Skip to main content
S&P 5007,619.98-0.48%DOW52,421.20-0.29%NASDAQ26,186.41-0.56%BTC$76,883.00-1.17%ETH$2,477.54-1.29%GOLD$4,323.90-0.64%OIL$102.35+0.95%
Smart Investors Daily
Barinthus Biotherapeutics plc logo

NASDAQ · BRNS

Barinthus Biotherapeutics plc

Healthcare · Biotechnology

$0.74

Down-$0.02 (-2.49%)

Updated Sep 15, 2026, 12:14 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
29.6M
P/E ratio
-0.39
Dividend yield
0.00%
52-week range
$0.51 – $1.83
Volume
378.15K
Avg. volume
144.91K

Price performance

BRNS price history

1M range · 16 trading sessions · Daily adjusted prices

BRNS closed at $0.74 after 16 trading sessions, up 24.70% for the selected period.

Last close
$0.74
Period change
+24.70%
Period low
$0.59
Period high
$0.77
Daily close
View OHLC price history
BRNS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 8, 2026$0.7443$0.769$0.6415$0.7401378.15K
Sep 4, 2026$0.788$0.8222$0.7001$0.759226.79K
Sep 3, 2026$0.7204$0.743$0.70$0.719437.84K
Sep 2, 2026$0.758$0.79$0.7192$0.743190.95K
Sep 1, 2026$0.73$0.77$0.73$0.765204.53K
Aug 31, 2026$0.73$0.76$0.6964$0.697196.99K
Aug 28, 2026$0.731$0.7495$0.70$0.746331.32K
Aug 27, 2026$0.715$0.7594$0.69$0.731278.8K
Aug 26, 2026$0.64$0.7111$0.64$0.706466.39K
Aug 25, 2026$0.6501$0.68$0.6379$0.6647.2K
Aug 24, 2026$0.63$0.63$0.6031$0.60319.71K
Aug 21, 2026$0.63$0.63$0.6191$0.621711.68K
Aug 20, 2026$0.6262$0.6262$0.6123$0.61236.49K
Aug 19, 2026$0.6201$0.6508$0.5802$0.60239.96K
Aug 18, 2026$0.616$0.66$0.615$0.6274.58K
Aug 17, 2026$0.608$0.66$0.591$0.593544.4K

Latest BRNS news

The latest Smart Investors Daily articles mentioning BRNS.

Stock researchCompany · Overview

BRNS research

Overview

Company profile and research snapshot.

Company profile

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.00
Implied upside
—
Analysts
—
BRNS recent ratings
DateFirmRatingTarget
Nov 17, 2025HC Wainwright & Co.Buy—
Mar 21, 2025HC Wainwright & Co.Buy—
Jan 13, 2025HC Wainwright & Co.Buy—
Nov 19, 2024HC Wainwright & Co.Buy—
Nov 8, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 24, 2026

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market openTopco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus

defenseworld.net · Dec 11, 2025

Contrasting Barinthus Biotherapeutics (NASDAQ:BRNS) & Oncobiologics (NASDAQ:OTLK)

Oncobiologics (NASDAQ: OTLK - Get Free Report) and Barinthus Biotherapeutics (NASDAQ: BRNS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Valuation and Earnings This table compares Oncobiologics and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By